Enhancing HCC Treatment: Innovatively Combining HDAC2 Inhibitor with PD-1/PD-L1 Inhibition

The authors review the application of ideal histone deacetylases 2 (HDAC2) inhibitors with solid anti-tumor efficacy in combination with immunotherapy for HCC.